MatriSys Bioscience

Often the first thing MatriSys Bioscience Inc. ’s team needs to explain to potential investors is that microbiome therapy isn’t focused solely on gastrointestinal disorders, although that’s an easier

2018 looks set to be the year when the microbiome comes of age, clinically at least. Data are expected from early clinical studies using an array of approaches, which, if successful, will drive increa

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar